These findings highlight the overarching importance of even small changes in ADAR regulatory cascade, and suggest that AZIN1 RNA editing may serve as a potential prognostic biomarker in GC patients, and may assist in clinical decision-making for deciding pre-operative treatment strategies in GC patients, as we usher into the era of precision medicine for cancer patients. The gene discussed is ADAR; the disease is cancer.